Abstract
Notwithstanding substantial improvement of the results by the introduction of cisplatin and carboplatin into the treatment strategy against ovarian cancer, the majority of the patients still face a grim prognosis (1,2,3,4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.P. Neijt, W.W. ten Bokkel Huinink, M.E.L. van der Burg, et al., Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma, The Lancet 2:594–600 (1984).
J.P. Neijt, W.W. ten Bokkel Huinink, M.E.L. van der Burg, Longterm results of combination chemotherapy in advanced ovarian cancer, Proceedings of the 15th Congress of ESMO, Annals of Oncology, Vol. 1, pag. 14, abstr. p.2:22 (1990).
W.W. ten Bokkel Huinink, M.E.L. van der Burg, A.T. van Oosterom, et al, Longterm results of a study comparing carboplatin with cisplatin in combination chemotherapy against ovarian cancer, Proceedings 15th Congress of ESMO, Annals of Oncology, Vol.1, pag. 9, abstr. p.2:1 (1990).
D.S. Alberts, R. Canetta R, and N. Mason-Liddil, Carboplatin in the first line chemotherapy of ovarian cancer, Seminars in Oncology, Vol. 17, Nr. 1 (suppl. II, Febr.):54–60 (1990).
B.C. Behrends, K.R. Rotzinger, T.C. Hamilton, et al., Cytotoxicity of three cisplatin analogues in a drug sensitive and a new cisplatin resistant human ovarian cancer cell line, ASCO Proceedings (1985).
R.F. Ozols, Pharmacologic reversal of drug resistance in ovarian cancer, Seminars in Oncology, Vol. 12, Nr. 3, (suppl. 4, Sept.) (1985).
L. Levin, W. Hryniuk, Dose intensity analysis of advanced ovarian carcinoma, J. of Clin, Oncol, 5:576–681 (1986).
R.F. Ozols, Y. Ostchega, C.E. Myers, et al., Cisplatin in hypertonic saline in refractory ovarian cancer, J. of Clin, Oncol, 3:1246–1250 (1985).
W.W. ten Bokkel Huinink, S. Rodenhuis, G. Simonetti, et al., Studies with carboplatin in ovarian cancer: experience of the Netherlands Cancer Institute and GCCG of the European Organization for research and treatment of cancer. In: Carboplatin (JM-8) Current Perspectives and future directions, Edited by P.A. Bunn Jr, R. Canetta, R.F. Ozols, and M. Rozencweig, W.B Saunders company, Philadelphia (1990).
T.C. Shea, M. Flaherty, A. Elias, et al., Phase I clinical and pharmacokinetic study of carboplatin with autologous bone marrow support. J. Clin. Oncol. Vol. 7, No.5: 651–661 (1989).
D. Metcalf, Biological properties in vitro of a recombinant human granulocyte-macrophage colony stimulating factor, Blood, 67: 37–45 (1986).
W.P. Steward, J.H. Scarffe, R. Austin, P. Crowther and Loynds, Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor, Proc. ASCO: Vol. 7:189 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
ten Bokkel Huinink, W.W. (1991). Phase I/II Study to Further Escalate the Dose of Carboplatin in Combination with GM-CSF in the Treatment of Refractory Ovarian Cancer. In: Howell, S.B. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0738-7_39
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0738-7_39
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0740-0
Online ISBN: 978-1-4899-0738-7
eBook Packages: Springer Book Archive